3D Medicines Inc. (HKG:1244)
Hong Kong · Delayed Price · Currency is HKD 5.93
-0.06 (-1.00%)
Jul 18, 2025, 4:08 PM HKT
3D Medicines Revenue
In the year 2024, 3D Medicines had annual revenue of 445.65M CNY, down -29.81%. 3D Medicines had revenue of 239.23M in the half year ending December 31, 2024, a decrease of -33.62%.
Revenue
445.65M CNY
Revenue Growth
-29.81%
P/S Ratio
3.06
Revenue / Employee
2.33M CNY
Employees
191
Market Cap
1.45B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 445.65M | -189.30M | -29.81% |
| Dec 31, 2023 | 634.95M | 67.56M | 11.91% |
| Dec 31, 2022 | 567.39M | 507.13M | 841.57% |
| Dec 31, 2021 | 60.26M | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| Akeso | 2.26B |
| Sino Biopharmaceutical | 30.72B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |